[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369114-105":59,"doc-detail-369114-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-effect-between-metabolic-syndrome-and-life-expectancy-after-cancer-diagnosis-catalan-cohort-study","The effect between metabolic syndrome and life expectancy after cancer diagnosis - Catalan cohort study","","Study of remaining life expectancy (RLE) after cancer diagnosis evaluates how age, sex, cancer type, and metabolic syndrome (MS) components relate to survival. Data come from the SIDIAP database in Catalonia from 2006–2017, analyzing RLE across 13 cancer types. A cohort of 183,364 individuals is followed from diagnosis to death, transfer, or the end of study (December 2017). RLE at age 68 is calculated for MS components (0, 1, 2, ≥3), revealing sex- and cancer-specific gradients. Increased MS components generally reduce RLE, and MS-targeted prevention may improve outcomes.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-effect-between-metabolic-syndrome-and-life-expectancy-after-cancer-diagnosis-catalan-cohort-study/369114/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-effect-between-metabolic-syndrome-and-life-expectancy-after-cancer-diagnosis-catalan-cohort-study/369114.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study measure after a cancer diagnosis?","Question",{"text":112,"@type":113},"It measures remaining life expectancy (RLE) and examines how RLE changes with age, sex, cancer type, and metabolic syndrome components.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data source and time period does the cohort study use?",{"text":117,"@type":113},"The study uses the SIDIAP database in Catalonia covering 2006–2017, with follow-up from diagnosis until death, transfer, or study end (December 2017).",{"name":119,"@type":110,"acceptedAnswer":120},"How are metabolic syndrome components categorized in the analysis?",{"text":121,"@type":113},"RLE is calculated by MS component count, grouped as 0, 1, 2, and ≥3 components.",{"name":123,"@type":110,"acceptedAnswer":124},"What overall conclusion is drawn about MS components and life expectancy?",{"text":125,"@type":113},"Higher numbers of MS components are associated with reduced RLE for multiple cancer types in both men and women, suggesting that prevention strategies targeting MS components could improve life expectancy after cancer.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369114,1792237590,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","López‑Jiménez etal. BMC Public Health (2025) 25:178  \n[https://doi.org/10.1](https://doi.org/10.1) 186/s12889‑025‑21437‑9  \nBMC Public Health  \n RESEARCH Open Access  \nThe effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study  \nTomàs López‑Jiménez 1,2, Oleguer Plana‑Ripoll3,4, Talita Duarte‑Salles 1,5, Anna Palomar‑Cros 1,6 and Diana Puente 1,6*  \nAbstract  \nThis study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006–2017) . RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individu‑ als followed from diagnosis until death, transfer, or study end (December 2017) . RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3) . Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS compo‑ nents versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non‑Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non‑Hodgkin lymphoma and the smallest in pan‑ creatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients.  \nKeywords Metabolic syndrome, Cancer, Remaining life expectancy, Survival  \n*Correspondence: Diana Puente [dpuente@idiapjgol.org](dpuente@idiapjgol.org)  \n1 Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Gran Via de Les Corts Catalanes, 587 Àtic, 08007 Barcelona, Spain  \n2 Programa de Doctorat en Metodologia de la Recerca Biomèdica i Salut Pública, Universitat Autònoma de Barcelona, Barcelona (Cerdanyola del Vallès), Spain  \n3 Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark  \n4 National Center for Register‑Based Research, Aarhus University, Aarhus, Denmark  \n5 Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands  \n6 Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola de Vallès), Barcelona, Spain  \nIntroduction  \nMetabolic syndrome (MS) forms a cluster of metabolic dysregulations including insulin resistance, dyslipidemia, central obesity, and hypertension. MS is significantly associated with an increased risk of developing diabetes and cardiovascular diseases [1]. Moreover, some studies [2–4] found an association between MS and a higher risk of liver, colorectal and bladder cancer in men; and endometrial, pancreatic, colorectal, ovarian and post-menopausal breast cancer in women.  \nMS is associated with a 1.5-fold increase in the risk of all-cause mortality [5]. Recent studies have examined MSand its components with cancer recurrence and overall mortality [6, 7]. The relationship between MS and cancer is complex; individual components of the MS are known risk factors for incident cancer disease, but it is not clear how the clustering of these components is linked to the  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence ","cbCaih2fC4SFOVQA","https://ap.wps.com/l/cbCaih2fC4SFOVQA","pdf",1937356,12,"English","# Abstract\n# Introduction\n## Metabolic syndrome and cancer risk\n## Remaining life expectancy and study rationale\n# Material and methods\n## Data source and setting","[{\"question\":\"What does the study measure after a cancer diagnosis?\",\"answer\":\"It measures remaining life expectancy (RLE) and examines how RLE changes with age, sex, cancer type, and metabolic syndrome components.\"},{\"question\":\"What data source and time period does the cohort study use?\",\"answer\":\"The study uses the SIDIAP database in Catalonia covering 2006–2017, with follow-up from diagnosis until death, transfer, or study end (December 2017).\"},{\"question\":\"How are metabolic syndrome components categorized in the analysis?\",\"answer\":\"RLE is calculated by MS component count, grouped as 0, 1, 2, and ≥3 components.\"},{\"question\":\"What overall conclusion is drawn about MS components and life expectancy?\",\"answer\":\"Higher numbers of MS components are associated with reduced RLE for multiple cancer types in both men and women, suggesting that prevention strategies targeting MS components could improve life expectancy after cancer.\"}]","The effect between metabolic syndrome and life expectancy after cancer diagnosis - Catalan cohort study | PDF",1790180826,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0216c05b3062566956a19e01a00917e6.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b82d50782203c7a239c799726ffd21d.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dde079e9058fbe344dc1d81c9e788e5.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f6da082ec1b0c6c78b17db660ca2cd2.webp",980,1301]